pragiola 100 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 100 mg - urbroj: svaka tvrda kapsula sadrži 100 mg pregabalina
pragiola 150 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 150 mg - urbroj: svaka tvrda kapsula sadrži 150 mg pregabalina
pragiola 200 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 200 mg - urbroj: svaka tvrda kapsula sadrži 200 mg pregabalina
pragiola 225 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 225 mg - urbroj: svaka tvrda kapsula sadrži 225 mg pregabalina
pragiola 25 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 25 mg - urbroj: svaka tvrda kapsula sadrži 25 mg pregabalina
pragiola 300 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 300 mg - urbroj: svaka tvrda kapsula sadrži 300 mg pregabalina
pragiola 50 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 50 mg - urbroj: svaka tvrda kapsula sadrži 50 mg pregabalina
pragiola 75 mg tvrde kapsule
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - прегабалин - kapsula, tvrda - 75 mg - urbroj: svaka tvrda kapsula sadrži 75 mg pregabalina
clevor
orion corporation - ропинирол hidroklorid - Дофаминергические agenti, agonisti dopamina - psi - izazivanje povraćanja kod pasa.
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.